Tirzepatide, a dual GIP and GLP-1 receptor agonist approved by the FDA for type 2 diabetes and chronic weight management, modulates hunger signals rather than eliminating them entirely
Today 38 (8), 716725
Many patients who achieve good control initially find their A1C levels creeping up year after year despite adhering to their treatment plans
Clinically, SIRS includes respiratory symptoms, ranging in severity from mild tachypnea to respiratory failure, persistent pulmonary hypertension, irritability, lethargy, temperature instability, poor perfusion and hypotension, disseminated intravascular coagulation, poor feeding, vomiting and ileus
At 300 mcg, which is the standard current protocol, the effect size is likely more modest still
What does prior authorization look like under the Bridge